Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

, SNY

Sanofi

$44.88

-0.05 (-0.11%)

06:26
10/15/19
10/15
06:26
10/15/19
06:26

Europe 1 List changes at BofA/Merrill

BofA/Merrill added Roche (RHHBY) and Sanofi (SNY) to the Europe 1 List and removed AstraZeneca.

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$44.88

-0.05 (-0.11%)

NVS

Novartis

$85.96

-0.66 (-0.76%)

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

RHHBY Roche
$0.00

(0.00%)

09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.
07/23/19
JPMS
07/23/19
NO CHANGE
JPMS
Neutral
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth. Overall, the analyst maintains her view that Roche (RHHBY) and PTC Therapeutics' (PTCT) Risdiplam represents a key potential competitive threat to Spinraza given the convenience of oral dosing and with filing for Risdiplam anticipated in the second half of 2019, in addition to Zolgensma's launch, Fye does not see questions related to competition for Spinraza dissipating anytime soon. The analyst reiterates a Neutral rating on Ions Pharmaceuticals' shares.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.
07/26/19
UBSW
07/26/19
UPGRADE
UBSW
Buy
Roche upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded Roche to Buy from Neutral and raised his price target for the shares to CHF 300 from CHF 270. The company's legacy portfolio, built around Herceptin and Rituxan, is showing greater resilience while its "credible" neuroscience pipeline is taking shape, Leuchten tells investors in a research note. As such, he now sees Roche's business model as less challenged.
SNY Sanofi
$44.88

-0.05 (-0.11%)

09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy from Neutral at Guggenheim
10/02/19
STFL
10/02/19
NO CHANGE
Target $45
STFL
Buy
Stifel remains buyer of Principia Biopharma into Q4 data readouts
Stifel analyst Derek Archila remains bullish and a buyer of Principia Biopharma (PRNB) shares ahead of the company's two Phase 2 readouts for PRN1008 in immune thrombocytopenia and pemphigus vulgaris. The shares could reach the mid-$50 range if results are positive, Archila tells investors in a research note. He believes the bogey for each study is not that high and keeps a Buy rating on Principia with a $45 price target. The two clinical catalysts, coupled with Phase 2 data expected in the first half of 2020 from the company's partnered program with Sanofi (SNY) in multiple sclerosis, offers "multiple shots for valuation creation" over the next nine months.
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
NVS Novartis
$85.96

-0.66 (-0.76%)

09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
08/13/19
OPCO
08/13/19
NO CHANGE
Target $230
OPCO
Outperform
Amgen price target raised to $230 from $210 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.
10/08/19
PIPR
10/08/19
NO CHANGE
Target $435
PIPR
Overweight
Piper positive on Regeneron after 'significant let-down' Novartis label
Piper Jaffray analyst Christopher Raymond is "incrementally positive" on Regeneron Pharmaceuticals (REGN) after the FDA approved Novartis' (NVS) Beovu for the treatment of wet age-related macular degeneration. While the approval was anticipated and physician anticipation of the drug has been high, doctors are likely to view the drug's label "as a significant let-down," Raymond tells investors in a research note. The analyst says that with inflammation and immunogenicity rates meaningfully higher than Regeneron's Eylea, and the lack of flexibility to dose more frequently, he sees little reason for doctors to switch. And while some investors may point to price as another meaningful lever, off-label Avastin makes for an "insurmountable bar for the price-sensitive segment," says Raymond. He keeps an Overweight rating on Regeneron shares with a $435 price target. The label "renders Beovu as little more than an also-ran," contends the analyst. As such, Raymond thinks Eylea's dominance in remains intact.

TODAY'S FREE FLY STORIES

GE

General Electric

$11.35

0.37 (3.37%)

, DAL

Delta Air Lines

$57.04

1.95 (3.54%)

12:07
12/12/19
12/12
12:07
12/12/19
12:07
On The Fly
Fly Intel: Wall Street's top stories at midday »

With yesterday's Fed…

GE

General Electric

$11.35

0.37 (3.37%)

DAL

Delta Air Lines

$57.04

1.95 (3.54%)

LUV

Southwest

$54.99

1.01 (1.87%)

BA

Boeing

$346.65

-3.35 (-0.96%)

LULU

Lululemon

$222.97

-10.34 (-4.43%)

AMRX

Amneal Pharmaceuticals

$5.15

1.665 (47.78%)

CIEN

Ciena

$40.86

5.41 (15.26%)

PLAB

Photronics

$16.39

1.28 (8.47%)

RH

RH

$220.00

-13 (-5.58%)

NDSN

Nordson

$162.80

-4.64 (-2.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 23

    Jan

  • 29

    Jan

MRVL

Marvell

$25.53

0.75 (3.03%)

12:05
12/12/19
12/12
12:05
12/12/19
12:05
Options
Marvell call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

CVS

CVS Health

$74.11

0.735 (1.00%)

12:03
12/12/19
12/12
12:03
12/12/19
12:03
Periodicals
CVS to make gene sequencing test access easier for cancer patients, Reuters says »

CVS Health said it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$201.83

-0.4 (-0.20%)

12:02
12/12/19
12/12
12:02
12/12/19
12:02
Hot Stocks
Facebook introduces Facebook Pay to simplify payments »

Deborah Liu, VP,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.64

0.325 (2.27%)

, PUGOY

Peugeot

$0.00

(0.00%)

12:01
12/12/19
12/12
12:01
12/12/19
12:01
Periodicals
Fiat, PSA Group aim to sign merger agreement next week, Bloomberg reports »

Fiat Chrysler Automobiles…

FCAU

Fiat Chrysler

$14.64

0.325 (2.27%)

PUGOY

Peugeot

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

FB

Facebook

$201.80

-0.43 (-0.21%)

12:01
12/12/19
12/12
12:01
12/12/19
12:01
Periodicals
Facebook to delay naming oversight board members until 2020, Reuters reports »

Facebook will delay the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$40.89

5.44 (15.35%)

12:00
12/12/19
12/12
12:00
12/12/19
12:00
Hot Stocks
Ciena rises 15.4% »

Ciena is up 15.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DBD

Diebold

$9.93

2.175 (28.05%)

12:00
12/12/19
12/12
12:00
12/12/19
12:00
Hot Stocks
Diebold rises 28.4% »

Diebold is up 28.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$5.21

1.725 (49.50%)

12:00
12/12/19
12/12
12:00
12/12/19
12:00
Hot Stocks
Amneal Pharmaceuticals rises 49.1% »

Amneal Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKI

PerkinElmer

$95.54

1.19 (1.26%)

11:56
12/12/19
12/12
11:56
12/12/19
11:56
Hot Stocks
FDA authorizes PerkinElmer test to aid in newborn screening for DMD »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,754.57

5.46 (0.31%)

11:56
12/12/19
12/12
11:56
12/12/19
11:56
Periodicals
Breaking Periodicals news story on Amazon.com »

Amazon.com announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
12/12/19
12/12
11:55
12/12/19
11:55
General news
Treasury's $75 B 4- and 8-week bill auctions garnered mixed results »

Treasury's $75 B 4-…

11:55
12/12/19
12/12
11:55
12/12/19
11:55
Conference/Events
William Blair financial services/insurance analyst to hold a luncheon »

Financial…

11:55
12/12/19
12/12
11:55
12/12/19
11:55
Conference/Events
William Blair software/IT services to hold a group luncheon »

Enterprise Software &…

TOL

Toll Brothers

$39.55

-0.565 (-1.41%)

, DHI

D.R. Horton

$54.73

-1.17 (-2.09%)

11:51
12/12/19
12/12
11:51
12/12/19
11:51
Recommendations
Toll Brothers, D.R. Horton analyst commentary  »

Toll Brothers added to…

TOL

Toll Brothers

$39.55

-0.565 (-1.41%)

DHI

D.R. Horton

$54.73

-1.17 (-2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$85.31

2.14 (2.57%)

11:48
12/12/19
12/12
11:48
12/12/19
11:48
Conference/Events
Autoliv management to meet with Mizuho »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

AAPL

Apple

$269.52

-1.19 (-0.44%)

11:46
12/12/19
12/12
11:46
12/12/19
11:46
Periodicals
Apple supplier reaches agreement for $736M bailout, Bloomberg reports »

Apple supplier Japan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRBT

iRobot

$49.39

3.15 (6.81%)

11:45
12/12/19
12/12
11:45
12/12/19
11:45
Options
iRobot call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
12/12/19
12/12
11:45
12/12/19
11:45
Conference/Events
The Empire Club of Canada holds a luncheon meeting »

The Bank of Canada…

COUP

Coupa Software

$137.90

-6.21 (-4.31%)

11:43
12/12/19
12/12
11:43
12/12/19
11:43
Conference/Events
Coupa Software management to meet with Needham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

  • 06

    Jan

FIVN

Five9

$65.32

-0.08 (-0.12%)

11:42
12/12/19
12/12
11:42
12/12/19
11:42
Conference/Events
Five9 management to meet with Needham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

FORM

FormFactor

$25.31

1.54 (6.48%)

11:41
12/12/19
12/12
11:41
12/12/19
11:41
Conference/Events
FormFactor management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

11:39
12/12/19
12/12
11:39
12/12/19
11:39
Conference/Events
JPMorgan biotechnology analysts to hold an analsyt/industry conference call »

Biotech Analysts Kasimov,…

11:34
12/12/19
12/12
11:34
12/12/19
11:34
Conference/Events
JPMorgan payment/IT services analyst to hold an analyst/industry conference call »

Payments, Processors…

ICE

IntercontinentalExchange

$91.48

-0.87 (-0.94%)

11:33
12/12/19
12/12
11:33
12/12/19
11:33
Hot Stocks
ICE announces first block trade of Bakkt Bitcoin Monthly Options »

Intercontinental Exchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.